KR20200018485A - 우울 장애들의 치료 - Google Patents

우울 장애들의 치료 Download PDF

Info

Publication number
KR20200018485A
KR20200018485A KR1020197038042A KR20197038042A KR20200018485A KR 20200018485 A KR20200018485 A KR 20200018485A KR 1020197038042 A KR1020197038042 A KR 1020197038042A KR 20197038042 A KR20197038042 A KR 20197038042A KR 20200018485 A KR20200018485 A KR 20200018485A
Authority
KR
South Korea
Prior art keywords
parenteral administration
pharmaceutically acceptable
pharmaceutical compositions
acceptable salt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197038042A
Other languages
English (en)
Korean (ko)
Inventor
매튜 듀링
Original Assignee
오비드 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오비드 테라퓨틱스 인크. filed Critical 오비드 테라퓨틱스 인크.
Publication of KR20200018485A publication Critical patent/KR20200018485A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197038042A 2017-05-24 2018-05-22 우울 장애들의 치료 Ceased KR20200018485A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762510481P 2017-05-24 2017-05-24
US62/510,481 2017-05-24
US15/933,673 US20180338959A1 (en) 2017-05-24 2018-03-23 Treatment of depressive disorders
US15/933,673 2018-03-23
PCT/US2018/033848 WO2018217718A1 (en) 2017-05-24 2018-05-22 Treatment of depressive disorders

Publications (1)

Publication Number Publication Date
KR20200018485A true KR20200018485A (ko) 2020-02-19

Family

ID=64395877

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038042A Ceased KR20200018485A (ko) 2017-05-24 2018-05-22 우울 장애들의 치료

Country Status (10)

Country Link
US (4) US20180338959A1 (https=)
EP (2) EP3630065A4 (https=)
JP (2) JP2020520963A (https=)
KR (1) KR20200018485A (https=)
CN (2) CN115105499A (https=)
AU (1) AU2018272819A1 (https=)
CA (1) CA3064299A1 (https=)
IL (1) IL270781A (https=)
MX (1) MX393452B (https=)
WO (1) WO2018217718A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
HK1258616A1 (zh) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. 神经活性类固醇、组合物、及其用途
US10987303B2 (en) * 2018-05-02 2021-04-27 LifeMax Laboratories, Inc. Extended release suspension formulation of lurasidone
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2020168337A1 (en) 2019-02-17 2020-08-20 Magid Abraham Compositions and methods for treatment of depression and other disorders
KR102085938B1 (ko) * 2019-11-04 2020-03-06 한국메탈실리콘 주식회사 실리콘 복합체 제조방법
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
DK1641456T3 (da) * 2003-06-25 2010-06-21 Lundbeck & Co As H Gaboxadol til behandling af depression og andre affektive lidelser
CL2004001603A1 (es) * 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US10628156B2 (en) * 2013-07-09 2020-04-21 Texas Instruments Incorporated Vector SIMD VLIW data path architecture
DK3151832T3 (da) * 2014-06-06 2021-06-14 Ovid Therapeutics Inc Fremgangsmåder til øgning af tonisk hæmning og behandling af sekundær søvnløshed
IL256912B2 (en) * 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
KR20220035195A (ko) * 2019-07-15 2022-03-21 오비드 테라퓨틱스 인크. 치료적 치료를 위한 가복사돌을 포함하는 약학적 제제

Also Published As

Publication number Publication date
EP3630065A1 (en) 2020-04-08
EP3939587A1 (en) 2022-01-19
US20180338959A1 (en) 2018-11-29
US20190117633A1 (en) 2019-04-25
AU2018272819A1 (en) 2019-12-05
JP2020520963A (ja) 2020-07-16
CN110996910A (zh) 2020-04-10
US20210379028A1 (en) 2021-12-09
US20200179351A1 (en) 2020-06-11
JP2023061957A (ja) 2023-05-02
WO2018217718A1 (en) 2018-11-29
MX2019014024A (es) 2020-02-17
EP3630065A4 (en) 2021-03-24
MX393452B (es) 2025-03-24
IL270781A (en) 2020-01-30
CN115105499A (zh) 2022-09-27
CA3064299A1 (en) 2019-11-29

Similar Documents

Publication Publication Date Title
US20210379028A1 (en) Treatment of depressive disorders
JP6328855B2 (ja) 即効型インスリン組成物
JP2018184440A (ja) うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
TWI763632B (zh) 用於重症治療時之鎮靜方法及非口服調配物
US10117830B2 (en) Stable parenteral DNJ compositions
JP2020528929A (ja) ストレス関連障害を治療するための組成物
CA3074563A1 (en) Sublingual epinephrine tablets
US20220110917A1 (en) Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
CN107961215B (zh) 一种左西替利嗪注射剂
HK40027257A (en) Treatment of depressive disorders
KR20120089444A (ko) 정맥내 이부프로펜에 의한 위독한 환자의 치료방법
WO2025120013A1 (en) Compositions and methods for treating depression disorders
WO2026013454A1 (en) Multi-dose pen of tirzepatide
HK40121582A (zh) 用於治疗癫痫性紊乱的方法和组合物
HK1256349A1 (zh) 用於在危重监护治疗期间使用的镇静方法和肠胃外制剂
HK1214956B (zh) 稳定的肠胃外dnj组合物
HK40007677A (en) Methods and compositions for treatment of epileptic disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210520

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230302

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231004

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230302

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I